# Cellectis

FDA RMAT designation June 2026 for allogeneic TALEN-edited UCART22 in r/r B-ALL; Phase 1 100% response rate; pivotal trial initiated — only allogeneic CAR-T in a pivotal trial globally.

Source: https://en.bioecon.ru/companies/cellectis/
Updated: 2026-06-24

- Country: France
- Ticker: CLLS

## Verifiable facts

| Fact | Value | Source |
| --- | --- | --- |
| Revenue | $14.5 million in consolidated revenues and other income for the six-month period ended June 30, 2026 | https://ml.globenewswire.com/Resource/Download/774d0b7a-6940-4418-94f2-73049e7e4c74 |
| Production site | Paris, France (55,000 sq ft facility); Raleigh, NC (82,000 sq ft facility); New York, NY (25,000 sq ft facility) | https://www.cellectis.com/en/products/manufacturing |
| Capacity | 1 batch produces 100s of doses, scalable to 1000s of doses [medium confidence] | https://www.cellectis.com/uploads/files/Corporate_Presentation_-_March_2026.pdf, https://www.cellectis.com/uploads/files/Corporate_Presentation_-_May_2026_2.pdf |
| Regulatory approval | FDA RMAT designation granted to lasme-cel (UCART22) in June 2026 | https://allsci.com/news/expedited-pathways/cellectis-allogeneic-cd22-car-t-receives-fda-rmat-designation-for-relapsed-refractory-b-all/, https://finance.yahoo.com/sectors/healthcare/articles/cellectis-receives-fda-rmat-designation-203000364.html, https://www.cellectis.com/uploads/files/PRESS_RELEASE-RMAT_designation.pdf |
| Headquarters | Paris, France | https://finance.yahoo.com/sectors/healthcare/articles/cellectis-receives-fda-rmat-designation-203000364.html, https://www.cellectis.com/uploads/files/PRESS_RELEASE-RMAT_designation.pdf |
| Funding | $169 million in consolidated cash, cash equivalents and fixed-term deposits as of June 30, 2026 | https://ml.globenewswire.com/Resource/Download/774d0b7a-6940-4418-94f2-73049e7e4c74, https://www.cellectis.com/uploads/files/Earnings_Q1_2026_PR_English.pdf |

Independent sources: allsci.com, finance.yahoo.com, ml.globenewswire.com

## Technologies

- [CAR-T cell therapy](https://en.bioecon.ru/technology/car-t-cell-therapy/)
- [Personalized & regenerative medicine](https://en.bioecon.ru/technology/personalized-regenerative-medicine/)